Synthesis, structure, NO donor activity of iron–sulfur nitrosyl complex with 2-aminophenol-2-yl and its antiproliferative activity against human cancer cells
- 27 September 2013
- journal article
- research article
- Published by Taylor & Francis in Journal of Coordination Chemistry
- Vol. 66 (20) , 3602-3618
Abstract
A new tetranitrosyl binuclear iron complex, [Fe2(SC6H6N)2(NO)4] (1), has been synthesized by two methods. Molecular and crystalline structure of 1 were determined by X-ray analysis; the complex is binuclear of “μ-S” type with ~2.7052(4) Å between the irons. The compound crystallizes in monoclinic, space group P21/n, Z = 2; parameters of the unit cell: a = 6.6257(2) Å, b = 7.9337(2) Å, c = 16.7858(4) Å, β = 96.742(2)°, V = 876.26(4) Å3. Parameters of Mössbauer spectrum for 1 are: isomer shift δFe = 0.096(1) mm/s, quadrupole splitting ΔEQ = 1.122(1) mm/s, line width 0.264(1) mm/s at 293 K. As follows from the electrochemical analysis of aqueous solutions of 1, it generates NO in protonic media without additional activation. NO amount and the rate of its activation are much higher in acidic solutions than in neutral and alkali ones. The constants of hydrolytic decomposition of 1 were calculated. The geometry and electronic structure of isolated 1 were studied using the density functional theory. Differential sensitivity of four lines of human tumor cells of various genesis to 1 has been determined (ovarian carcinoma (SCOV3), large intestine cancer (LS174T), mammary gland carcinoma (MCF7), and non-small cell carcinoma of lung (A549)); dependence of tumor cells amount on the complex concentration has been studied in order to use the complex as a promising antitumor agent for trials in vivo.Keywords
This publication has 32 references indexed in Scilit:
- Nitric Oxide: Cancer Target or Anticancer Agent?Current Cancer Drug Targets, 2009
- YC-1 [3-(5′-Hydroxymethyl-2′-furyl)-1-benzyl Indazole] Inhibits Endothelial Cell Functions Induced by Angiogenic Factors in Vitro and Angiogenesis in Vivo ModelsThe Journal of Pharmacology and Experimental Therapeutics, 2005
- Tumor Cell Responses to a Novel Glutathione S-Transferase–Activated Nitric Oxide-Releasing ProdrugMolecular Pharmacology, 2004
- Iron complexes acting as nitric oxide carriersInorganica Chimica Acta, 2003
- YC-1: A Potential Anticancer Drug Targeting Hypoxia-Inducible Factor 1JNCI: Journal of the National Cancer Institute, 2003
- Nitric oxide donor increases the efficiency of cytostatic therapy and retards the development of drug resistanceNitric Oxide, 2003
- Influence of the nitric oxide donor glyceryl trinitrate on apoptotic pathways in human colon cancer cellsGastroenterology, 2002
- Nitric Oxide‐Releasing DrugsAnnals of the New York Academy of Sciences, 2002
- Repair of Nitric Oxide-modified Ferredoxin [2Fe-2S] Cluster by Cysteine Desulfurase (IscS)Journal of Biological Chemistry, 2002
- Donors of NO and pulsed radiation at λ=820 nm exert effects on cell attachment to extracellular matricesToxicology Letters, 2001